U.S. markets closed

Axcella Health Inc. (AXLA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.6300+0.2900 (+8.68%)
At close: 4:00PM EDT
3.6500 +0.02 (0.55%)
After hours: 05:21PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close3.3400
Open3.3900
Bid3.4000 x 800
Ask3.6800 x 1000
Day's Range3.3600 - 3.6300
52 Week Range3.0300 - 6.8400
Volume58,663
Avg. Volume331,308
Market Cap136.932M
Beta (5Y Monthly)1.40
PE Ratio (TTM)N/A
EPS (TTM)-1.6040
Earnings DateAug 03, 2021 - Aug 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.13
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Axcella to Report Second Quarter 2021 Financial Results on July 29, 2021
    Business Wire

    Axcella to Report Second Quarter 2021 Financial Results on July 29, 2021

    CAMBRIDGE, Mass., July 22, 2021--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that it plans to report its second quarter 2021 financial results and other business updates on July 29, 2021. The company will host a conference call at 8:30 a.m. ET that morning.

  • Axcella Announces Initiation of EMMPOWER℠ Phase 2 Clinical Trial of AXA1665
    Business Wire

    Axcella Announces Initiation of EMMPOWER℠ Phase 2 Clinical Trial of AXA1665

    CAMBRIDGE, Mass., June 30, 2021--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that it has activated initial clinical sites and patient screening for its global Phase 2 clinical trial of AXA1665, the company’s multi-targeted oral product candidate for the reduction in risk of recurrent overt hepatic encephalopathy (OHE).

  • Axcella Accumulating Assets; Multiple Therapies in the Pipeline
    TipRanks

    Axcella Accumulating Assets; Multiple Therapies in the Pipeline

    Time in the market beats timing the market, as the old adage goes. This platitude plays particularly well regarding biotechnology stocks, as one will want to be invested in these stocks well before any big news comes out. Axcella Health Inc. (AXLA) is no exception, as the company is making strides on breakthrough therapies. Analysts are bullish on the stock. One such analyst is Keay Nakae of Chardan Capital Markets, who assigned a Buy rating and a price target of $10. While this price target rep